National Center for the Advancement of Translational Sciences of the National Institute of Health has modified its organizational structure.
SUPPLEMENTARY INFORMATION:
Part N, National Institutes of Health (NIH), of the Statement of Organization and Functions for the Department of Health and Human Services (HHS), is amended as set forth below to reflect the reorganization of the National Institute of Health, National Center for the Advancement of Translational Science (NCATS) by retitling and updating the functional Statements (1) the Chemical Genomics Branch to the Translational Models Branch under the Division of Preclinical Innovation within NCATS, (2) revise functional statement of the Office of Special initiatives, (3) abolishing the Office of Drug Development Partnership Programs, and the Office of Translational Medicine under the Office of the Director within NCATS.
Section N,
Organization and Functions,
is amended as follows:
(1) In the
Division of Preclinical Innovation (N92, formerly HN92)
retitle the following:
Chemical Genomics Branch (N924, formerly HN924)
to
Translational Models Branch (N924, formerly HN924).
(1) Develop and advance human-based Non-Animal Models (NAMs) as transformative drug discovery and biomedical research tools; (2) Accelerate therapeutic discovery and regulatory science for rare and common diseases using predictive human model systems; (3) Accelerate target discovery using predictive human model systems; (4) Establish the predictive value and usefulness of human-based NAMs as pharmacology and toxicology assessment tools to reduce reliance on animal models; (5) Generate high-quality human biological data to enable AI-driven predictive modeling of drug efficacy and toxicity; (6) Integrate stem cells, tissue engineering, functional genomics, toxicology and data science into a unified human-based translational research enterprise; and (7) Serve as an NIH-wide resource for advancing human-based models research and technologies.
( printed page 74592)
(2)
In the Office of the Director (N91, formerly HN91)
revise functional statement of the following:
Office of Special Initiatives (N917, formerly HN917).
(1) Provides transformative programs extramurally that address barriers and bottlenecks to pre-clinical and clinical translation; (2) Drives development and dissemination of novel and disruptive technologies, approaches, and solutions for issues that impede translational research through promotion to the scientific, research, and industry sectors; (3) Incentivizes groundbreaking expansion of the therapeutic landscape for rare and chronic diseases through discovery and exploration of novel therapeutic targets and programs; and (4) Promotes and engenders partnerships and interagency collaborations with key stakeholders including government, industry, and academia, to advance innovation in early-stage clinical trials.
(3) In the
Office of the Director (N91, formerly HN91)
remove the following:
Office of Drug Development Partnership Programs (N918, formerly HN918)
Office of Translational Medicine (N919, formerly HN919)
Use this for formal legal and research references to the published document.
91 FR 74591
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Statement of Organization, Functions, and Delegations of Authority,” thefederalregister.org (November 19, 2026), https://thefederalregister.org/documents/2026-23537/statement-of-organization-functions-and-delegations-of-authority.